Title |
Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer
|
---|---|
Published in |
Frontiers in oncology, March 2017
|
DOI | 10.3389/fonc.2017.00038 |
Pubmed ID | |
Authors |
Barbara Melosky |
Abstract |
The treatment paradigm for metastatic non-small cell, non-squamous lung cancer is continuously evolving due to new treatment options and our increasing knowledge of molecular signal pathways. As a result of treatments becoming more efficacious and more personalized, survival for selected groups of non-small cell lung cancer (NSCLC) patients is increasing. In this paper, three algorithms will be presented for treating patients with metastatic non-squamous, NSCLC. These include treatment algorithms for NSCLC patients whose tumors have EGFR mutations, ALK rearrangements, or wild-type/wild-type tumors. As the world of immunotherapy continues to evolve quickly, a future algorithm will also be presented. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 50% |
Switzerland | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Members of the public | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 52 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 9 | 17% |
Student > Bachelor | 6 | 12% |
Other | 6 | 12% |
Student > Doctoral Student | 3 | 6% |
Professor | 3 | 6% |
Other | 9 | 17% |
Unknown | 16 | 31% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 14 | 27% |
Biochemistry, Genetics and Molecular Biology | 6 | 12% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 10% |
Nursing and Health Professions | 2 | 4% |
Chemistry | 2 | 4% |
Other | 5 | 10% |
Unknown | 18 | 35% |